The Valley Desk

LetterLeukemiaPublished

Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUS

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Letter
Venue
Leukemia
Published
PubMed ID
42613435
PubMed Central ID
PMC13713553
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal